Sign in

Private company

Eiger BioPharmaceuticals, Inc.

In its 2024 annual report the company says: “We are a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases.”3 It is headquartered in Palo Alto, California.1

Last updated Oct 21, 2026.

Overview

  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersPalo Alto, California1
  • Business address2155 Park Boulevard, Palo Alto, Ca 943062
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

We are a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases. All of our rare disease programs in our portfolio have FDA Breakthrough Therapy designation.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-455.1%Operating margin4
-475.3%Net margin4
17.0%Revenue growth, 20234
-$74.8MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Cost of revenue0¢$24.0K
  • Research and development67¢$62.3M
  • Selling, general and admin27¢$25.2M
  • Interest6¢$5.5M
  • Income tax0¢$6.0K

Out of $15.8M in revenue.4 The company lost money this year.

Financial statements

Revenue54$15.8M in 2023
0$5.0M$10.0M$15.0M$20.0M2020: $0$020202021: $12.1M$12.1M20212022: $13.5M$13.5M2022+11%2023: $15.8M$15.8M2023+17%
Operating income67854-$71.8M in 2023+73% since 2017
-$100.0M-$75.0M-$50.0M-$25.0M02017: -$41.5M-$41.5M20172018: -$51.0M-$51.0M2018+23%2019: -$68.9M-$68.9M2019+35%2020: -$62.1M-$62.1M2020−10%2021: -$76.9M-$76.9M2021+24%2022: -$92.7M-$92.7M2022+21%2023: -$71.8M-$71.8M2023−23%
Net income67854-$75.0M in 2023+77% since 2017
-$100.0M-$75.0M-$50.0M-$25.0M02017: -$42.4M-$42.4M20172018: -$52.4M-$52.4M2018+23%2019: -$70.3M-$70.3M2019+34%2020: -$65.1M-$65.1M2020−7%2021: -$33.9M-$33.9M2021−48%2022: -$96.8M-$96.8M2022+185%2023: -$75.0M-$75.0M2023−23%
Fiscal year2017201820192020202120222023
Revenue$05$12.1M5$13.5M4$15.8M4
Cost of revenue$05$745.0K5$1.8M4$24.0K4
Research and development$29.5M6$37.1M7$51.8M8$41.6M5$64.4M5$75.3M4$62.3M4
Selling, general and admin$17.1M8$20.6M5$23.9M5$29.1M4$25.2M4
Operating expenses$89.1M5$106.2M4$87.6M4
Operating income-$41.5M6-$51.0M7-$68.9M8-$62.1M5-$76.9M5-$92.7M4-$71.8M4
Interest$1.5M6$2.3M7$3.4M8$3.6M5$3.6M5$4.1M4$5.5M4
Income before tax-$33.9M5-$96.8M4-$75.0M4
Income tax$06$07$08$05$64.0K5$23.0K4$6.0K4
Net income-$42.4M6-$52.4M7-$70.3M8-$65.1M5-$33.9M5-$96.8M4-$75.0M4
Earnings per share-$2.315-$1.005-$69.744-$50.784
Earnings per share (diluted)-$2.315-$1.005-$69.744-$50.784
Shares (weighted, basic)33.9M shares51.4M shares41.5M shares4
Shares (weighted, diluted)33.9M shares51.4M shares41.5M shares4

Compare Eiger BioPharmaceuticals, Inc. with another company

Corporate structure

Eiger BioPharmaceuticals, Inc. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Eiger BioPharmaceuticals, Inc.

  • Moshe Arkin Filed SC 13G on Eiger BioPharmaceuticals, Inc., latest Aug 26, 2024 (7 filings since Mar 8, 2022)
  • Ameriprise Financial Filed SC 13G/A on Eiger BioPharmaceuticals, Inc., latest May 10, 2024 (6 filings since Jan 21, 2022)
  • 683 Capital Management, LLC Filed SC 13G/A on Eiger BioPharmaceuticals, Inc., latest Feb 14, 2024 (3 filings since Feb 14, 2022)
  • Propel Bio Management, LLC Filed SC 13D/A on Eiger BioPharmaceuticals, Inc., latest Nov 3, 2023 (4 filings since Aug 15, 2023)
  • BlackRock Filed SC 13G/A on Eiger BioPharmaceuticals, Inc., latest Jul 7, 2023 (3 filings since Feb 3, 2022)
  • ADAGE CAPITAL PARTNERS GP, L.L.C. Filed SC 13G/A on Eiger BioPharmaceuticals, Inc., latest Feb 9, 2023 (2 filings since May 2, 2022)
  • Vivo Ventures VI, LLC Filed SC 13D/A on Eiger BioPharmaceuticals, Inc., latest Feb 11, 2022
  • Eiger BioPharmaceuticals, Inc. Palo Alto, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Eiger BioPharmaceuticals, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$1.8M4 Dec 31, 2023$1.6M4 Dec 31, 2022+12.9%
Accumulated depreciation$1.2M4 Dec 31, 2023$895.0K4 Dec 31, 2022+30.7%
Property and equipment, net$627.0K4 Dec 31, 2023$696.0K4 Dec 31, 2022−9.9%
Operating-lease assets (leased space)$561.0K5 Dec 31, 2022$653.0K5 Dec 31, 2021−14.1%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$25.4M4 Dec 31, 2023$25.8M4 Dec 31, 2022−1.4%
Marketable securities, current$73.1M5 Dec 31, 2022$66.6M8 Dec 31, 2021+9.8%
Debt securities available for sale$73.2M4 Dec 31, 2022$83.9M5 Dec 31, 2021−12.8%

Inventory

ItemLatestA year beforeChange
Inventory, total$1.6M4 Dec 31, 2023$2.9M4 Dec 31, 2022−45.5%
Raw materials$531.0K4 Dec 31, 2023$1.7M4 Dec 31, 2022−68.8%
Work in process$940.0K4 Dec 31, 2023$884.0K4 Dec 31, 2022+6.3%
Finished goods$85.0K4 Dec 31, 2023$266.0K4 Dec 31, 2022−68.0%

Leadership

Who has led Eiger BioPharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Krisztina M. Zsebo2014–2015
  2. David A. Cory2016–2022
  3. David Apelian2023

President

  1. Krisztina M. Zsebo2014
  2. Paul B. Cleveland2014–2015
  3. David A. Cory2016–2022

Chief financial officer

  1. Paul B. Cleveland2014–2015
  2. James H. Welch2016–2018
  3. Sriram Ryali2018–2022
  4. William G. Kachioff2023

Chief operating officer

  1. David Apelian2018–2019
201520202025
Board members and other officers (34)

Former names

  • Celladon CorpOct 5, 2004 to Mar 23, 20162

Timeline

  1. Oct 1, 20248-K Bankruptcy or receivership; Change to shareholders' rights; Other events52
  2. Sep 9, 20248-K Bankruptcy or receivership; Change to shareholders' rights53
  3. Sep 4, 20248-K Completed an acquisition or sale54
  4. Sep 3, 20248-K Regulation FD disclosure55
  5. Aug 2, 20248-K Entered a material agreement56
  6. Aug 1, 20248-K Regulation FD disclosure57
  7. Jul 16, 20248-K Regulation FD disclosure58
  8. Jul 10, 20248-K Completed an acquisition or sale59
  9. Jul 1, 20248-K Regulation FD disclosure60
  10. Jun 21, 20248-K Entered a material agreement61
  11. Jun 14, 20248-K Entered a material agreement62
  12. May 28, 20248-K Regulation FD disclosure63
  13. Feb 2, 2023New chief executive David Apelian becomes CEO12
  14. Mar 28, 2016New chief executive David A. Cory becomes CEO13
  15. Jan 29, 2014New chief executive Krisztina M. Zsebo becomes CEO14

Calendar

When it reported results

  1. Nov 9, 2023Reported quarterly or annual results64
  2. Aug 14, 2023Reported quarterly or annual results65
  3. May 11, 2023Reported quarterly or annual results66
  4. Mar 16, 2023Reported quarterly or annual results67
  5. Nov 3, 2022Reported quarterly or annual results68
  6. Aug 4, 2022Reported quarterly or annual results69
  7. May 5, 2022Reported quarterly or annual results70
  8. Mar 10, 2022Reported quarterly or annual results71

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

154 filings to the SEC since October 2021: 4 annual reports, 7 quarterly reports, 48 major events, 45 insider forms, 26 large holders, 24 other. The latest 20:

  1. Oct 1, 202415-12G EDGAR
  2. Oct 1, 20248-K EDGAR
  3. Sep 9, 20248-K EDGAR
  4. Sep 4, 20248-K EDGAR
  5. Sep 3, 20248-K EDGAR
  6. Aug 26, 2024SC 13G EDGAR
  7. Aug 2, 20248-K EDGAR
  8. Aug 1, 20248-K EDGAR
  9. Jul 16, 20248-K EDGAR
  10. Jul 10, 20248-K EDGAR
  11. Jul 1, 20248-K EDGAR
  12. Jul 1, 2024SC 13D/A EDGAR
  13. Jun 21, 20248-K EDGAR
  14. Jun 14, 20248-K EDGAR
  15. May 28, 20248-K EDGAR
  16. May 10, 2024SC 13G/A EDGAR
  17. May 8, 20248-K EDGAR
  18. May 2, 20248-K EDGAR
  19. Apr 29, 202410-K/A EDGAR
  20. Apr 25, 202425-NSE EDGAR

The 154 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

13 open-market trades by officers, directors and large owners since October 2021: 6 buys and 7 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 2, 2023KAYNE RICHARD A10% ownerBuy23,398$0.30$7.0KForm 4
Nov 1, 2023KAYNE RICHARD A10% ownerBuy100,000$0.28$28.0KForm 4
Oct 31, 2023KAYNE RICHARD A10% ownerBuy154,841$0.24$37.6KForm 4
Oct 31, 2023KAWAS LEEN10% ownerBuy24,332$0.26$6.3KForm 4
Mar 17, 2023Mayer Eldon C. IIIEx VP & Chief Commerc. OfficerSale4,395$1.07$4.7KForm 4
Jan 23, 2023Dietz Thomas JohnDirectorBuy50,000$1.43$71.5KForm 4
Dec 29, 2022Murray ChristineDirectorSale5,000$1.22$6.1KForm 4
Dec 22, 2022Dietz Thomas JohnDirectorSale22,500$1.17$26.3KForm 4
Dec 22, 2022Glenn Jeffrey SDirectorBuy100,000$1.28$128.0KForm 4
Aug 16, 2022Apelian DavidCEOSale5,000$9.81$49.0KForm 4
Mar 14, 2022Ryali SriramChief Financial OfficerSale2,266$5.60$12.7KForm 4
Mar 14, 2022Mayer Eldon C. IIIEx VP & Chief Commerc. OfficerSale1,657$5.60$9.3KForm 4
Jan 7, 2022Mayer Eldon C. IIIEx VP & Chief Commerc. OfficerSale1,560$4.95$7.7KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Eiger BioPharmaceuticals, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAREiger BioPharmaceuticals, Inc.1
  • CIK0001305253
  • Employer ID (EIN)36-10041301
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address2155 Park Boulevard, Palo Alto, CA 943061
  • Phone650-279-98451
  • Shares outstanding1,480,797 as of Apr 24, 202479
  • Public float$30.0M as of Jun 30, 202379
  • On EDGAR sinceOct 5, 20041
  • Filings694 in all: 4 (190), 8-K (158), 3 (50), SC 13G/A (45), 10-Q (30), SC 13G (27), CORRESP (16), 424B5 (13)1
    All 42 form types

    425 (12), SC 13D/A (12), 10-K (11), DEF 14A (11), S-8 (11), S-8 POS (11), 4/A (10), D (10), DEFA14A (8), UPLOAD (8), CT ORDER (7), EFFECT (7), S-1/A (6), REGDEX (5), S-3 (5), SC 13D (5), 8-K/A (3), 424B4 (2), ARS (2), D/A (2), S-1 (2), S-3/A (2), S-4/A (2), 10-K/A (1), 15-12G (1), 25-NSE (1), 424B3 (1), 8-A12B (1), CERTNAS (1), DRS (1), NT 10-K (1), PRE 14A (1), S-1MEF (1), S-4 (1)

  • Latest filingsAnnual report (10-K) Apr 8, 2024
    Quarterly report (10-Q) Nov 9, 2023
    Proxy statement (DEF 14A) Dec 11, 2023
    Latest 8-K (8-K) Oct 1, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79